Reading view
Tumor Cell and Brain Microenvironment Interactions in Non-small Cell Lung Cancer Brain Metastasis: Mechanisms and Emerging Insights
Zhongguo Fei Ai Za Zhi. 2026 Jul 20;29(7):548-556. doi: 10.3779/j.issn.1009-3419.2026.102.21.
ABSTRACT
Brain metastasis in non-small cell lung cancer (NSCLC) is shaped by continuous interactions between tumor cells and the brain-specific microenvironment. Vascular, glial and immune components contribute to intracranial colonization, immune escape and therapeutic resistance, while single-cell and spatial omics reveal heterogeneity in cellular states, communication networks and spatial niches. This review summarizes NSCLC brain metastasis and intracranial colonization, the brain metastatic microenvironment and tumor-microenvironment interactions, and discusses the heterogeneity revealed by single-cell and spatial omics and its potential relevance to therapeutic response and patient stratification. .
PMID:42705858 | DOI:10.3779/j.issn.1009-3419.2026.102.21
SHP1 expression in tumor-associated dendritic cells drives immunoevasion via impairing CD8<sup>+</sup> memory T cell responses
Oncogenesis, Published online: 15 May 2026; doi:10.1038/s41389-026-00627-z
SHP1 expression in tumor-associated dendritic cells drives immunoevasion via impairing CD8+ memory T cell responsesLeptomeningeal metastatic cancer cells induce a permissive choroid plexus vasculature through extracellular-vesicle-derived 5-HIAA signaling
Nature Cancer, Published online: 03 April 2026; doi:10.1038/s43018-026-01145-y
Huang, Hou, Yang et al. demonstrate that leptomeningeal metastatic cells favor the formation of a premetastatic niche by remodeling the choroid plexus vasculature through the serotonin metabolite 5-hydroxyindoleacetic acid, which signals into endothelial cells through the aryl hydrocarbon receptor.PromptForge-350k: A Large-Scale Dataset and Contrastive Framework for Prompt-Based AI Image Forgery Localization
Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer
J Inflamm Res. 2026 Mar 17;19:581764. doi: 10.2147/JIR.S581764. eCollection 2026.
ABSTRACT
Immune checkpoint inhibitors (ICIs) have significantly improved the clinical outcomes for patients with non-small cell lung cancer (NSCLC). However, patient heterogeneity and the limitations of current biomarkers contribute to variations in therapeutic responses. Identifying potential beneficiaries of immunotherapy and predicting efficacy remain critical challenges. In recent years, artificial intelligence (AI) has become increasingly applied in cancer treatment, particularly for modeling clinical data and predicting patient prognosis. By integrating multi-omics data such as radiomics, pathomics, genomics, transcriptomics, proteomics, and microbiomics, AI enables comprehensive biomarker discovery and facilitates prediction of immunotherapy responses and potential toxicities in NSCLC patients. Despite these advancements, challenges such as data standardization, limited interpretability, and technical barriers persist. This review summarizes the application of AI in predicting immunotherapy efficacy for NSCLC patients and discusses the challenges and future directions in the context of precision medicine.
PMID:41867453 | PMC:PMC13005593 | DOI:10.2147/JIR.S581764
β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer
Adaptation of Agentic AI: A Survey of Post-Training, Memory, and Skills
Taming Modality Entanglement in Continual Audio-Visual Segmentation
Maximizing carrier extraction in hybrid back-contact silicon solar cells
Nature, Published online: 10 March 2026; doi:10.1038/s41586-026-10351-8
Maximizing carrier extraction in hybrid back-contact silicon solar cells